(154) Incidence of Chemotherapy Induced Peripheral Neuropathy in Patients Using Cryotherapy Prevention and Receiving Treatment with Taxane-based Chemotherapy

Poster Abstract:

Background: Chemotherapy induced peripheral neuropathy (CIPN) is a common complication in patients receiving taxane-based treatment regimens which can lead to chemotherapy dose reductions, drug discontinuations, and significant patient discomfort. There are many treatment options available to treat CIPN but strategies to prevent CIPN are limited. Currently, neither ESMO or ASCO have strong recommendations for modalities to prevent chemotherapy induced neuropathy. Cryotherapy is one method studied for prevention shown to have mixed results in regards to efficacy in preventing CIPN. Cryotherapy consists of placing ice packs on the hands and feet to cause vasoconstriction of blood vessels in an effort to reduce the amount of cytotoxic chemotherapy delivered to these areas. Current practice at our institution is to educate all patients receiving taxane-based chemotherapy on potential benefits of cryotherapy to help decrease the risk of developing peripheral neuropathy. If patients choose to proceed with cryotherapy, it is their responsibility to obtain and bring cryotherapy products, such as ice packs, cold gloves and socks to the chemotherapy infusion appointment.

Objective: The purpose of this study was to evaluate the incidence of CIPN between patients receiving taxane-based chemotherapy and utilizing cryotherapy and patients receiving taxane-based therapy and not utilizing cryotherapy.

Methods: This study was a retrospective chart review conducted at a single site cancer center. Adult patients who started a new treatment regimen with taxane-based therapy (paclitaxel, docetaxel, nab-paclitaxel) in the pre-determined time frame were assigned to either the cryotherapy group, or non-cryotherapy group. Patients were assigned to the cryotherapy or non-cryotherapy group on the basis of cryotherapy utilization on Day 1 of Cycle 1 of the taxane-based chemotherapy treatment. The primary outcome was overall incidence of CIPN in patients in the cryotherapy group compared to the non-cryotherapy group. Secondary outcomes included time, in days, to taxane dose reduction or discontinuation due to peripheral neuropathy and time, in days, to dose increases or addition of medications used to treat peripheral neuropathy.

Results: Not available

Discussion/

Conclusion: Not available

References (must also be included in final poster): 1. Winters-Stone KM, Horak F, Jacobs PG, et al. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol. 2017;35(23):2604-2612. doi:10.1200/JCO.2016.71.3552.
2. Hershman DL, Till C, Wright JD, et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016;34(25):3014-3022. doi:10.1200/JCO.2015.66.2346.
3. Hammi C, Yeung B. Neuropathy. [Updated 2022 Oct 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542220/.
4. Sundar R, Bandla A, Tan SS, et al. Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a pilot study. Front Oncol. 2016;6:274.
5. Beijers AJM, Bonhof CS, Mols F, et al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2020;31(1):131-136. doi:10.1016/j.annonc.2019.09.006.
6. Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306-1319. doi:10.1016/j.annonc.2020.07.003.
7. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399.